21:43:16 EDT Fri 15 May 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Chinook defendant Sabzevari appeals conviction

2026-05-15 19:54 ET - Street Wire

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Mike Caswell

Seyedfarbod Sabzevari, a California man recently sentenced by a U.S. federal judge to 14 months in prison for insider trading in Vancouver-Seattle biopharmaceutical listing Chinook Therapeutics Inc., has filed an appeal. Prosecutors claimed that Mr. Sabzevari was part of a group that realized $600,000 in gains from a $3.2-billion takeover offer made by Novartis AG. (All figures are in U.S. dollars.) A jury convicted him and others after a 13-day trial in December, 2025.

Mr. Sabzevari's appeal is contained in a brief notice filed in federal court in New Jersey on May 13, 2026. The single-sentence document provides no details of Mr. Sabzevari's appeal, simply stating that he is seeking to overturn the final judgment against him. Also appealing is one of his co-defendants, James Roberge, a Massachusetts man who received two months in prison for the same scheme.

The appeals come just over a week after the judge sentenced the two men for their parts in the scheme. The government claimed that Mr. Sabzevari, 31, learned about the takeover through his job, which included scheduling board meetings for Chinook. He worked for Ross Haghighat, a Boston resident also charged for the scheme. Prosecutors claimed that Mr. Haghighat tipped the others about the takeover after hearing about it during director meetings. The jury convicted him and the others after a 13-day trial, and his sentencing is scheduled for June 14, 2026.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2026 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.